Dr. Usman's Cardiology Notes

 Vericiguat in Heart Failure: Mechanism, Indications, Dosing, Evidence and Clinical Use Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator developed for patients with heart failure with reduced ejection fraction (HFrEF), particularly those who remain at high risk after a recent episode of worsening heart failure. Unlike the four foundational therapies of HFrEF, vericiguat is generally considered an additional treatment for selected high-risk patients rather than routine first-line therapy for every patient with reduced ejection fraction. Its clinical role became established largely through the VICTORIA trial, which demonstrated a reduction in the composite outcome of cardiovascular death or hospitalization for heart failure among patients with recently worsening HFrEF. --- What Is Vericiguat? Vericiguat is an oral soluble guanylate cyclase stimulator. It acts on the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (NO–sGC–cGMP) pathway, an importa...

Sacubitril/Valsartan Reduces Mortality More Than ACE Inhibitors in HFrEF Introduction Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality worldwide. For decades, ACE inhibitors were the cornerstone of therapy because they reduce mortality and hospitalization. However, the development of angiotensin receptor–neprilysin inhibitors (ARNIs), particularly sacubitril/valsartan, has significantly improved outcomes. Large randomized trials have demonstrated that sacubitril/valsartan reduces mortality and heart-failure hospitalizations more effectively than ACE inhibitors, leading to major changes in heart-failure guidelines. --- Mechanism of Action Sacubitril/valsartan combines two pharmacologic mechanisms: 1. Sacubitril (Neprilysin inhibitor) Inhibits neprilysin enzyme Prevents breakdown of natriuretic peptides Leads to: Vasodilation Natriuresis Reduced cardiac remodeling Decreased sympathetic activity 2. Valsartan (ARB) Blocks angiotensin II ...

Mortality Reducing Therapies in Chronic HFrEF: Evidence, Trials & Clinical Impact Heart failure with reduced ejection fraction (HFrEF) remains a major global cause of morbidity and mortality. Over the past three decades, rigorous randomized controlled trials (RCTs) have transformed management and proven that specific drugs and devices significantly reduce all-cause and cardiovascular mortality. Below is a comprehensive overview of each mortality-reducing therapy, its approximate relative mortality reduction, and the key landmark trials that shaped current guideline recommendations (AHA/ACC/HFSA & ESC). --- 1. Angiotensin Receptor Blockers (ARBs) — ~12% Mortality Reduction ARBs emerged as alternatives for patients intolerant to ACE inhibitors. They reduce afterload, neurohormonal activation, and remodeling. Landmark Trials • CHARM-Alternative (2003) Demonstrated mortality reduction in ACE-intolerant HFrEF patients with candesartan. • Val-HeFT (2001) Showed decreased HF hospitali...

KEY FACTS OF Peripartum Cardiomyopathy - PPCM Peripartum Cardiomyopathy (PPCM): The Heart Condition Every Clinician Should Recognize Pregnancy is often described as a physiological stress test for the body. While most women adapt remarkably well, a small number develop a rare but potentially life-threatening cardiac condition known as Peripartum Cardiomyopathy (PPCM). Despite improved awareness, PPCM continues to be underdiagnosed—mainly because its symptoms mimic normal pregnancy-related discomforts. In this article, we explore what PPCM is, how it presents, why it happens, and why early recognition makes all the difference. --- What Is Peripartum Cardiomyopathy? Peripartum cardiomyopathy is an idiopathic form of heart failure characterized by left ventricular systolic dysfunction that develops during a very specific period: **✔ From the last month of pregnancy ✔ To up to 5 months after delivery** Women must not have had any prior structural heart disease, and the LVEF is typically ...

Preoperative Cardiac Assessment: A Practical, Evidence-Based Guide for Clinicians Preoperative cardiac assessment is a critical step in ensuring safe surgery. Cardiovascular complications remain a major cause of perioperative morbidity and mortality, especially in patients with known or suspected heart disease. A systematic, guideline-based approach helps clinicians stratify risk, optimize patients, and communicate effectively with surgical teams. This article provides a practical, step-by-step framework based on current recommendations (ACC/AHA, ESC), written in simple, clinical language for quick application. --- 🔍 Why Preoperative Cardiac Assessment Matters Surgery induces physiologic stress (tachycardia, increased myocardial oxygen demand). Anaesthesia can cause hypotension, arrhythmias, and mask symptoms. Many patients with cardiovascular risk factors remain undiagnosed until exposed to perioperative stress. A structured assessment helps: ✓ Identify high-risk patients ✓ Reduce av...

Heart Failure: The Cardiology Topic Clinicians Search Most Heart failure (HF) emerges as the single most searched cardiology topic globally. It is a “rapidly growing public health issue” affecting an estimated 64 million people worldwide. In fact, heart failure is now a leading cause of hospitalization and mortality. Clinicians and researchers alike are focused on HF because its prevalence is rising (due to aging populations and better survival after heart attacks) even as outcomes remain poor. This immense burden – high mortality, frequent readmissions and poor quality of life – makes heart failure a central concern in cardiology. Online search trends reflect this intensity: Google query volumes for “heart failure” closely mirror the condition’s real-world prevalence. In short, heart failure is an ever-present topic in cardiology practice and research, and clinicians worldwide continually seek information on its diagnosis and management. Understanding Heart Failure Heart failure...

 Your heart, that throbbing, beating muscle, is probably the most iconic organ in your body. No other organ gets its own holiday, or as much radio play. And you’re not likely to get a love note decorated with a kidney or a spleen, or even a brain, which is really what rules the emotions. Don’t get me wrong, the heart does some great things -- namely, it powers the entire circulatory system, transporting nutrients, oxygen, waste, heat, hormones, and immune cells throughout the body, over and over. But in the end, the heart does not make you love. It doesn’t break apart if you get dumped by your boo. And it’s not a lonely hunter. The truth is, the heart is really just a pump -- a big, wet, muscley brute of a pump. And it doesn’t care about poetry or chocolate, or why you’re crying. The heart only has one concern: maintaining pressure. If you’ve ever squeezed the trigger on a squirt gun or opened up a shaken can of soda, you’ve seen how fluids flow from areas of high pressure -- like ...